The abstract is read at the publisher; the summary is JClub's.
Lanreotide in autosomal dominant polycystic kidney disease did not improve glomerular filtration rate decline, though it suggested an effect on creatinine-estimated eGFR slope.
- Why it matters: Conflicting kidney-function endpoints can obscure whether somatostatin analogues truly preserve renal function in ADPKD, complicating treatment decisions.
- What they did: The LIPS trial was the last randomized evaluation of somatostatin analogues in ADPKD, assessing both measured GFR decline and creatinine-estimated GFR slope.
- The result: The trial’s mixed endpoint signals reinforce the Kidney Disease: Improving Global Outcomes guidance against prescribing somatostatin analogues solely to preserve kidney function in ADPKD.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.